Opus Genetics (IRD) Income from Continuing Operations (2010 - 2026)
Opus Genetics (IRD) posted quarterly Income from Continuing Operations of 65535000.0 for Q1 2026, down 699.79% year-over-year from 10926278.1 in Q1 2025, and down 972.76% quarter-over-quarter from 6109000.0 in Q4 2025.
Powered by 
Analysis
Opus Genetics (IRD) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Income from Continuing Operations for 17 consecutive years, with 65535000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 699.79% year-over-year to 65535000.0; the TTM figure through Mar 2026 stood at 96518000.0 (down 64.65% YoY), while the FY2025 annual figure was 39177000.0, up 31.9% from the prior year.
- Income from Continuing Operations slipped to 65535000.0 in Q1 2026 per IRD's latest filing, from 6109000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 33941000.0 in Q4 2022 and bottomed at 65535000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 9078941.18 across 5 years, with a median of 6595000.0 in 2022.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations surged 637.64% — and 2026, when it plunged 699.79%.
- Opus Genetics' Income from Continuing Operations stood at 33941000.0 in 2022, then slumped by 114.13% to 4795000.0 in 2023, then slumped by 632.74% to 35135000.0 in 2024, then jumped by 82.61% to 6109000.0 in 2025, then plunged by 972.76% to 65535000.0 in 2026.
- Business Quant data shows IRD's Income from Continuing Operations at 65535000.0 in Q1 2026, 6109000.0 in Q4 2025, and 17454000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Opus Genetics | 447.34 Mn | 358.53 Mn | - | -8.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8.10 Mn |
| Mar 31, 2026 | -65.54 Mn |
| Dec 31, 2025 | -6.11 Mn |
| Sep 30, 2025 | -17.45 Mn |
| Jun 30, 2025 | -7.42 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Dec 31, 2024 | -35.14 Mn |
| Sep 30, 2024 | -7.53 Mn |
| Jun 30, 2024 | -7.77 Mn |
| Mar 31, 2024 | -7.11 Mn |
| Dec 31, 2023 | -4.80 Mn |
| Sep 30, 2023 | 5.56 Mn |
| Jun 30, 2023 | -4.96 Mn |
| Mar 31, 2023 | -5.79 Mn |
| Dec 31, 2022 | 33.94 Mn |
| Sep 30, 2022 | -4.53 Mn |
| Jun 30, 2022 | -4.93 Mn |
| Mar 31, 2022 | -6.60 Mn |
| Dec 31, 2021 | -6.31 Mn |
| Sep 30, 2021 | -4.23 Mn |